Literature DB >> 18956590

Phytoceuticals: mighty but ignored weapons against Helicobacter pylori infection.

Sun-Young Lee1, Yong Woon Shin, Ki-Baik Hahm.   

Abstract

Helicobacter pylori (H. pylori) infection causes peptic ulcer disease, mucosa-associated lymphoid tissue (MALT) lymphomas and gastric adenocarcinomas, for which the pathogenesis of chronic gastric inflammation prevails and provides the pathogenic basis. Since the role of H. pylori infection is promoting carcinogenesis rather than acting as a direct carcinogen, as several publications show, eradication alone cannot be the right answer for preventing H. pylori-associated gastric cancer. Therefore, a non-antimicrobial approach has been suggested to attain microbe-associated cancer prevention through controlling H. pylori-related chronic inflammatory processes and mediators responsible for carcinogenesis. Phytoceutical is a term for plant products that are active on biological systems. Phytoceuticals such as Korean red ginseng, green tea, red wine, flavonoids, broccoli sprouts, garlic, probiotics and flavonoids are known to inhibit H. pylori colonization, decrease gastric inflammation by inhibiting cytokine and chemokine release, and repress precancerous changes by inhibiting nuclear factor-kappa B DNA binding, inducing profuse levels of apoptosis and inhibiting mutagenesis. Even though further unsolved issues are awaited before phytoceuticals are accepted as a standard treatment for H. pylori infection, phytoceuticals can be a mighty weapon for either suppressing or modulating the disease-associated footprints of H. pylori infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18956590     DOI: 10.1111/j.1751-2980.2008.00334.x

Source DB:  PubMed          Journal:  J Dig Dis        ISSN: 1751-2972            Impact factor:   2.325


  18 in total

Review 1.  Nontraditional therapies to treat Helicobacter pylori infection.

Authors:  Morris O Makobongo; Jeremy J Gilbreath; D Scott Merrell
Journal:  J Microbiol       Date:  2014-03-29       Impact factor: 3.422

2.  Effects of curcumin on Helicobacter pylori infection.

Authors:  Vaclav Vetvicka; Jana Vetvickova; Rafael Fernandez-Botran
Journal:  Ann Transl Med       Date:  2016-12

3.  Endoscopic gastritis: what does it mean?

Authors:  Sun-Young Lee
Journal:  Dig Dis Sci       Date:  2011-08       Impact factor: 3.199

4.  Erratum to effects of curcumin on Helicobacter pylori infection.

Authors: 
Journal:  Ann Transl Med       Date:  2017-03

Review 5.  A Comprehensive Review on Pharmacotherapeutics of Three Phytochemicals, Curcumin, Quercetin, and Allicin, in the Treatment of Gastric Cancer.

Authors:  Atousa Haghi; Haniye Azimi; Roja Rahimi
Journal:  J Gastrointest Cancer       Date:  2017-12

Review 6.  Dietary, non-microbial intervention to prevent Helicobacter pylori-associated gastric diseases.

Authors:  Young-Min Han; Jong-Min Park; Migyeong Jeong; Jun-Hwan Yoo; Won-Hee Kim; Seok-Pyo Shin; Weon-Jin Ko; Ki-Baik Hahm
Journal:  Ann Transl Med       Date:  2015-06

Review 7.  Current progress toward eradicating Helicobacter pylori in East Asian countries: differences in the 2013 revised guidelines between China, Japan, and South Korea.

Authors:  Sun-Young Lee
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

Review 8.  The biological responses to resveratrol and other polyphenols from alcoholic beverages.

Authors:  Lindsay Brown; Paul A Kroon; Dipak K Das; Samarjit Das; Arpad Tosaki; Vincent Chan; Manfred V Singer; Peter Feick
Journal:  Alcohol Clin Exp Res       Date:  2009-06-10       Impact factor: 3.455

9.  Progression from chronic atrophic gastritis to gastric cancer; tangle, toggle, tackle with Korea red ginseng.

Authors:  Yoon Jae Kim; Jun Won Chung; So Jung Lee; Ki Seok Choi; Ju Hyun Kim; Ki Baik Hahm
Journal:  J Clin Biochem Nutr       Date:  2010-04-10       Impact factor: 3.114

10.  Black tea and theaflavins assist healing of indomethacin-induced gastric ulceration in mice by antioxidative action.

Authors:  Biplab Adhikary; Sudhir Kumar Yadav; Kshama Roy; Sandip K Bandyopadhyay; Subrata Chattopadhyay
Journal:  Evid Based Complement Alternat Med       Date:  2010-09-29       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.